Moderna Swings to Profit, Raises Guidance

Moderna posted third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, as net income reached $162 million versus a $200 million loss in the same period last year. The vaccine maker ($MRNA) also raised its full-year 2026 revenue growth outlook to a range of 15% to 25%, up from a prior forecast of "up to 10%", while trimming its 2026 R&D spending guidance to about $2.7 billion from $2.9 billion.